Q: What is Soliris used for?

Soliris is used to treat the following conditions: Atypical hemolytic uremic syndrome Generalized myasthenia gravis Neuromyelitis optica spectrum disorder Others

Q: How does Soliris work?

The Complement System Soliris belongs to a class of medications known as complement inhibitors. The complement system is a group of proteins in the blood that are part of the body's natural immune response. While these proteins normally help fight off bacteria and viruses, in certain rare diseases, the system becomes overactive and begins attacking the body's own healthy cells. Targeting the C5 Protein The active ingredient in Soliris, eculizumab, is a laboratory-made protein called a monoclonal antibody. It is designed to target and bind to a specific protein in the complement system known as C5 . By attaching to C5, Soliris prevents it from breaking down into smaller pieces that would otherwise trigger the final, destructive stage of the complement cascade. How It Helps Specific Conditions By blocking the complement pathway, Soliris helps manage different diseases in the following ways: Paroxysmal Nocturnal Hemoglobinuria (PNH): It stops the immune system from rupturing red blood cells, which reduces the need for blood transfusions and lowers the risk of blood clots. Atypical Hemolytic Uremic Syndrome (aHUS): It prevents the immune system from damaging small blood vessels, which helps protect vital organs like the kidneys from blood clots and inflammation. Generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD): It prevents the complement system from attacking the junctions between nerves and muscles or the central nervous system, helping to reduce muscle weakness and neurological damage.

Q: What are the active ingredients in Soliris?

The active ingredient in Soliris is eculizumab .

Q: What are the side effects of Soliris?

Common side effects of Soliris may include: Headache Upper respiratory infection Nausea Always consult with a healthcare professional about potential side effects.

Q: What drug class is Soliris?

Soliris belongs to the complement inhibitor drug class.

Q: What is the dosage of Soliris and how do I take it?

Administration Soliris is given as an injection into a vein, known as an intravenous (IV) infusion. This procedure is performed by a healthcare professional in a medical setting, such as a doctor's office, clinic, or hospital. Dosing Schedule The treatment schedule generally consists of two phases: Induction phase: During the first few weeks of treatment, infusions are typically given once a week. Maintenance phase: After the initial period, the frequency usually changes to once every two weeks for as long as the treatment is needed. The length of each infusion session can vary but often takes less than an hour for adults. Healthcare providers will monitor you during and after the infusion for any signs of an infusion-related reaction. Missed Doses It is important to receive every scheduled dose. If you miss an appointment for your infusion, contact your healthcare provider right away to reschedule. Missing doses can lead to a return of symptoms or complications related to your underlying condition.

Q: Is Soliris safe during pregnancy and breastfeeding?

Pregnancy Data on the use of Soliris in pregnant women are limited. While animal studies using similar molecules have not shown a high risk of harm to the developing fetus, there is not enough evidence to confirm its safety in humans. Because Soliris is a monoclonal antibody, it may cross the placenta and potentially affect the fetus. If you are pregnant or planning to become pregnant, your doctor will help you weigh the risks of the untreated condition against the potential risks of the medication. It is generally recommended to use Soliris during pregnancy only if the benefits clearly outweigh the potential risks to the fetus. Breastfeeding It is currently unknown whether Soliris passes into human breast milk. Because many medications can be excreted in milk and have the potential to cause side effects in a nursing infant, caution is advised. Healthcare providers typically recommend deciding between breastfeeding or continuing treatment with Soliris based on the mother's medical need for the drug. You should consult with your doctor to determine the best course of action for your specific situation.

Q: What forms and strengths does Soliris come in?

Soliris is supplied in the following form: Intravenous Solution: A concentrated, preservative-free liquid provided in single-dose vials for administration into a vein. This medication is not available in oral forms such as tablets or capsules. It must be prepared and diluted by a healthcare professional before it is administered as an infusion.

Q: What is the FDA approval status of Soliris?

FDA Approval Status Soliris (eculizumab) received its initial FDA approval in March 2007. It is currently approved for the treatment of the following conditions: Paroxysmal nocturnal hemoglobinuria (PNH) Atypical hemolytic uremic syndrome (aHUS) Generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive Neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody-positive Boxed Warning The FDA has issued a boxed warning for Soliris due to the increased risk of serious and life-threatening meningococcal infections. These infections can progress rapidly and may become fatal if not recognized and treated early. Risk Evaluation and Mitigation Strategy (REMS) Because of the risk of meningococcal infection, Soliris is only available through a restricted distribution program called the Soliris REMS. Regulatory requirements for this program include: Prescriber Certification: Healthcare providers who prescribe Soliris must be enrolled and certified in the REMS program. Vaccination: Patients must be vaccinated against meningococcal disease at least two weeks before receiving the first dose. If the treatment must start immediately, the patient must receive appropriate preventive antibiotics. Patient Education: Patients must be informed of the risks and provided with a Medication Guide and a Patient Safety Card, which they are instructed to carry at all times during treatment and for three months after the last dose.

Question 1

What is Soliris?

Accepted Answer

Soliris is a monoclonal antibody that functions as a complement inhibitor. It works by binding to a specific protein in the immune system to prevent it from attacking and destroying healthy cells.

By blocking this process, the medication helps manage conditions where the immune system causes unintended damage to the body.

Question 2

What is Soliris used for?

Accepted Answer

Soliris is used to treat the following conditions:

Atypical hemolytic uremic syndrome
Generalized myasthenia gravis
Neuromyelitis optica spectrum disorder
Others

Question 3

How does Soliris work?

Accepted Answer

The Complement System

Soliris belongs to a class of medications known as complement inhibitors. The complement system is a group of proteins in the blood that are part of the body's natural immune response. While these proteins normally help fight off bacteria and viruses, in certain rare diseases, the system becomes overactive and begins attacking the body's own healthy cells.

Targeting the C5 Protein

The active ingredient in Soliris, eculizumab, is a laboratory-made protein called a monoclonal antibody. It is designed to target and bind to a specific protein in the complement system known as C5. By attaching to C5, Soliris prevents it from breaking down into smaller pieces that would otherwise trigger the final, destructive stage of the complement cascade.

How It Helps Specific Conditions

By blocking the complement pathway, Soliris helps manage different diseases in the following ways:

Paroxysmal Nocturnal Hemoglobinuria (PNH): It stops the immune system from rupturing red blood cells, which reduces the need for blood transfusions and lowers the risk of blood clots.
Atypical Hemolytic Uremic Syndrome (aHUS): It prevents the immune system from damaging small blood vessels, which helps protect vital organs like the kidneys from blood clots and inflammation.
Generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD): It prevents the complement system from attacking the junctions between nerves and muscles or the central nervous system, helping to reduce muscle weakness and neurological damage.

Question 4

What are the active ingredients in Soliris?

Accepted Answer

The active ingredient in Soliris is eculizumab.

Question 5

What are the side effects of Soliris?

Accepted Answer

Common side effects of Soliris may include:

Headache
Upper respiratory infection
Nausea

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Soliris?

Accepted Answer

Soliris belongs to the complement inhibitor drug class.

Question 7

What is the dosage of Soliris and how do I take it?

Accepted Answer

Administration

Soliris is given as an injection into a vein, known as an intravenous (IV) infusion. This procedure is performed by a healthcare professional in a medical setting, such as a doctor's office, clinic, or hospital.

Dosing Schedule

The treatment schedule generally consists of two phases:

Induction phase: During the first few weeks of treatment, infusions are typically given once a week.
Maintenance phase: After the initial period, the frequency usually changes to once every two weeks for as long as the treatment is needed.

The length of each infusion session can vary but often takes less than an hour for adults. Healthcare providers will monitor you during and after the infusion for any signs of an infusion-related reaction.

Missed Doses

It is important to receive every scheduled dose. If you miss an appointment for your infusion, contact your healthcare provider right away to reschedule. Missing doses can lead to a return of symptoms or complications related to your underlying condition.

Question 8

Is Soliris safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Data on the use of Soliris in pregnant women are limited. While animal studies using similar molecules have not shown a high risk of harm to the developing fetus, there is not enough evidence to confirm its safety in humans. Because Soliris is a monoclonal antibody, it may cross the placenta and potentially affect the fetus.

If you are pregnant or planning to become pregnant, your doctor will help you weigh the risks of the untreated condition against the potential risks of the medication. It is generally recommended to use Soliris during pregnancy only if the benefits clearly outweigh the potential risks to the fetus.

Breastfeeding

It is currently unknown whether Soliris passes into human breast milk. Because many medications can be excreted in milk and have the potential to cause side effects in a nursing infant, caution is advised.

Healthcare providers typically recommend deciding between breastfeeding or continuing treatment with Soliris based on the mother's medical need for the drug. You should consult with your doctor to determine the best course of action for your specific situation.

Question 9

What forms and strengths does Soliris come in?

Accepted Answer

Soliris is supplied in the following form:

Intravenous Solution: A concentrated, preservative-free liquid provided in single-dose vials for administration into a vein.

This medication is not available in oral forms such as tablets or capsules. It must be prepared and diluted by a healthcare professional before it is administered as an infusion.

Question 10

What is the FDA approval status of Soliris?

Accepted Answer

FDA Approval Status

Soliris (eculizumab) received its initial FDA approval in March 2007. It is currently approved for the treatment of the following conditions:

Paroxysmal nocturnal hemoglobinuria (PNH)
Atypical hemolytic uremic syndrome (aHUS)
Generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive
Neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody-positive

Boxed Warning

The FDA has issued a boxed warning for Soliris due to the increased risk of serious and life-threatening meningococcal infections. These infections can progress rapidly and may become fatal if not recognized and treated early.

Risk Evaluation and Mitigation Strategy (REMS)

Because of the risk of meningococcal infection, Soliris is only available through a restricted distribution program called the Soliris REMS. Regulatory requirements for this program include:

Prescriber Certification: Healthcare providers who prescribe Soliris must be enrolled and certified in the REMS program.
Vaccination: Patients must be vaccinated against meningococcal disease at least two weeks before receiving the first dose. If the treatment must start immediately, the patient must receive appropriate preventive antibiotics.
Patient Education: Patients must be informed of the risks and provided with a Medication Guide and a Patient Safety Card, which they are instructed to carry at all times during treatment and for three months after the last dose.

Question 11

What should I know about Soliris and cost?

Accepted Answer

Factors Influencing Cost

The price of Soliris can vary significantly depending on several factors, including your insurance plan, the dosage required for your condition, and where you receive your infusions. Because it is a specialty drug administered by a healthcare professional, costs typically include both the medication itself and the clinical fees for the infusion procedure.

Insurance Coverage

Most private insurance plans and government programs like Medicare or Medicaid provide coverage for Soliris, but they often require prior authorization. This means your doctor must prove the medication is medically necessary before the insurance company will agree to pay for it. Patients may still be responsible for deductibles, copays, or coinsurance amounts.

Financial Assistance Programs

The manufacturer offers a patient support program that provides personalized assistance, including help navigating insurance hurdles and identifying potential financial aid options for eligible patients. There may also be independent charitable foundations that offer grants to help cover treatment costs for specific rare diseases.

Biosimilar Options

Lower-cost versions of eculizumab, known as biosimilars, may be available. These medications are highly similar to Soliris and are intended to provide the same clinical benefits at a potentially lower price point. You should discuss with your healthcare provider or insurance company if a biosimilar is an option for your treatment plan.

Soliris

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Soliris

Hospitals.net Disclosure